ClinicalTrials.gg
RecruitingNCT06076668Updated Oct 17, 2023

Dexmedetomidine Infusion Versus Oral Melatonin for Prevention of Intensive Care Delirium

An interventional study of Dexmedetomidine and Melatonin 3 MG in Dexmedetomidine, Melatonin and Delirium, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Tanta University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
41st of 78
90 · median 98
Started
2023
with 4 others
No phase
19 of 78
5 open now
Primary completion
2024-10
later than 1 of 16 live
Registered
67th of 78
by date
Lead sponsor
4 of 78
Tanta University

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 41st largest by planned enrollment, is one of 5 that started in 2023, is one of 19 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 67th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

This study aims to compare the effect of dexmedetomidine infusion and oral melatonin on preventing delirium in intensive care unit (ICU) patients.

Read the detailed description

Delirium is experienced in 20% to 40% of the critically ill and up to 80% of mechanically ventilated (MV) medical or surgical patients . It is a confessional state that has been described as a transient global disorder of cognition, awareness, and attention and as such is not only challenging for the treating medical team, but also has a considerable impact on affected patients. It is associated with prolonged hospital length of stay and time on MV, deterioration in cognition, and increased morbidity and mortality causing additional health-care expenses.

03

Conditions studied

  • Dexmedetomidine
  • Melatonin
  • Delirium

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 21 years or older.
  • Either gender.
  • Healthy gastrointestinal function (patients tolerated oral medications by gavage or mouth).
  • Richmond Agitation Sedation Scale (RASS) >-1.
  • No basic delirium or mood changes before admission to intensive care unit(ICU).

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • History of irreversible brain disease consistent with severe dementia.
  • Patient admitted with a primary neurologic condition or injury (e.g., intracranial hemorrhage).
  • Heart rate (HR) less than 50 beats/ min or second- third degree heart block in the absence of a pacemaker.
  • Acute alcohol withdrawal requiring benzodiazepine administration.
  • History of hepatic encephalopathy or end-stage liver disease ( class B or C).
  • The expected duration of intensive care unit (ICU) stay less than 5 days.
  • Inability to obtain .
  • Pregnancy.
  • Allergy to dexmedetomidine or melatonin.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Group D (n=30)

    patients will receive intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.

    Drug: Dexmedetomidine

  • Experimental
    Group M (n=30)

    patients will receive oral melatonin tablet 3 mg at 9:00 p.m.

    Drug: Melatonin 3 MG

  • Placebo comparator
    Control group

    patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.

    Drug: Saline

Interventions

  • Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.

    Also known as: DEX group

  • DrugMelatoninStudies of MelatoninMelatonin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive oral melatonin tablet 3 mg 9:00 p.m.

    Also known as: N-acetyl-5-methoxytryptamine

  • DrugSaline

    Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. The incidence of delirium

    The incidence of delirium within 14 days from admission to the intensive care unit (ICU) or until ICU discharge before this time. Every 12 hours throughout the study.

    Time frame: 14 days from admission to intensive care unit

Secondary outcomes

  1. The onset of delirium. • Duration of delirium. • Frequency of delirium. • Length of ICU stay. • Total dose of Haloperidol per day.

    Delirium was assessed using Confusion Assessment Method for intensive care unit (CAM- ICU) score at admission to ICU and every 12hr throughout the study. The final CAM-ICU score ranges from 0-7 with 7 being most severe. CAM-ICU-7 scores were further categorized as 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.

    Time frame: 14 days from admission to intensive care unit

  2. Duration of delirium

    Delirium was assessed using Confusion Assessment Method for intensive care unit(CAM- ICU) score at admission to ICU and every 12hr throughout the study. The final CAM-ICU score ranges from 0-7 with 7 being most severe. CAM-ICU-7 scores were further categorized as 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.

    Time frame: 14 days from admission to intensive care unit

  3. Frequency of delirium

    Delirium was assessed using Confusion Assessment Method for intensive care unit(CAM- ICU)score at admission to ICU and every 12hr throughout the study. The final CAM-ICU score ranges from 0-7 with 7 being most severe. CAM-ICU-7 scores were further categorized as 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.

    Time frame: 14 days from admission to intensive care unit

  4. Total dose of Haloperidol per day

    Total dose of Haloperidol per day 14 days from admission to intensive care unit

    Time frame: 14 days from admission to intensive care unit

07

Study locations

1 of 1 sites recruiting
  • Tanta University
    Tanta, El-Gharbia 31527, Egypt
    Recruiting
    • Eslam M Salem, Msc · Contactsalemeslam913@gmail.com · 00201004415074
    • Ayman A Youssef, MD · Sub investigator
    • Ghada F El-baradey, MD · Sub investigator
    • Shaimaa F Abdelkader, MD · Sub investigator
    • Alaa M Abo Hagar, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.

Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2023
First posted
Oct 11, 2023
StartActual
Oct 16, 2023
Primary completionEst.
Oct 20, 2024
CompletionEst.
Oct 20, 2024
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06076668
Lead sponsor
Tanta University
Responsible party
eslam salem (Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Oct 11, 2023
Start date
Oct 16, 2023
Primary completion
Oct 20, 2024 (estimated)
Completion
Oct 20, 2024 (estimated)
Last update
Oct 17, 2023

Study contacts

Eslam Eslam, MD
Contact
salemeslam913@gmail.com
01004415074

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Melatonin

Start the discussion